Crossmark

Poly-3-hydroxybutyrate-co-3-hydroxyvalerate(PHBV)-Polyethylene glycol 20k(PEG20k) as a promising delivery system for PT2399 in the treatment of disc degeneration

Crossref DOI link: https://doi.org/10.1186/s13036-024-00407-6

Published Online: 2024-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Zhencong

Zhang, Weilin

Huang, Shengbang

Dai, Zhiwen

Liang, Jinguo

Qiu, Qiulan

Chen, Siyuan

Guo, Weixiong

Wang, Zhongwei

Wei, Jinsong
Funding

Funding for this research was provided by:

Basic and Applied Basic Research Foundation of Guangdong Province (2021A1515010975)
License Information

Text and Data Mining valid from 2024-01-22

Version of Record valid from 2024-01-22
More Information

Article History

Received: 1 December 2023

Accepted: 12 January 2024

First Online: 22 January 2024

Declarations

:

: The research was carried out following the principles of the Declaration of Helsinki and received approval from the Clinical Research Ethics Committee of the Affiliated Hospital of Guangdong Medical University(CREC Ref. No. PJKT2022-052).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below